Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVXL Anavex Life Sciences	$8.37 +2.4%	$8.90	$3.51 ▼ $14.44	$714.56M	0.82	1.22 million shs	690,591 shs
NUVB Nuvation Bio	$2.24 +3.2%	$2.01	$1.54 ▼ $3.97	$758.64M	1.42	2.21 million shs	2.36 million shs
VIR Vir Biotechnology	$4.55 +1.1%	$6.02	$4.32 ▼ $14.45	$628.98M	1.36	1.37 million shs	1.23 million shs
YMAB Y-mAbs Therapeutics	$3.86 +6.0%	$4.48	$3.55 ▼ $16.11	$174.77M	0.53	315,620 shs	140,191 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVXL Anavex Life Sciences	+0.62%	-3.37%	-7.37%	-3.54%	+89.56%
NUVB Nuvation Bio	-2.28%	+5.42%	+5.68%	-6.35%	-35.25%
VIR Vir Biotechnology	-4.26%	-19.79%	-19.21%	-53.03%	-55.36%
YMAB Y-mAbs Therapeutics	-12.50%	-6.19%	-26.17%	-41.00%	-69.20%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVXL Anavex Life Sciences	3.8052 of 5 stars	3.7	1.0	4.7	2.6	0.8	0.6
NUVB Nuvation Bio	3.5773 of 5 stars	4.6	0.0	0.0	2.8	5.0	0.6
VIR Vir Biotechnology	2.7437 of 5 stars	3.4	1.0	0.0	2.5	3.3	1.3
YMAB Y-mAbs Therapeutics	3.9785 of 5 stars	4.4	3.0	0.0	3.0	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVXL Anavex Life Sciences	3.33	Buy	$44.00	425.69% Upside
NUVB Nuvation Bio	3.17	Buy	$7.83	249.70% Upside
VIR Vir Biotechnology	2.86	Moderate Buy	$32.86	622.14% Upside
YMAB Y-mAbs Therapeutics	2.82	Moderate Buy	$16.70	332.64% Upside

Current Analyst Ratings Breakdown

Latest YMAB, VIR, AVXL, and NUVB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	NUVB Nuvation Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00
5/14/2025	YMAB Y-mAbs Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $14.00
5/14/2025	YMAB Y-mAbs Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$21.00 ➝ $20.00
5/12/2025	VIR Vir Biotechnology	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$19.00 ➝ $14.00
4/23/2025	NUVB Nuvation Bio	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
4/23/2025	NUVB Nuvation Bio	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Mkt Outperform	$6.00
4/23/2025	NUVB Nuvation Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Outperform	$6.00
4/22/2025	YMAB Y-mAbs Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Underperform	$3.00
4/17/2025	VIR Vir Biotechnology	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $21.00
4/7/2025	AVXL Anavex Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00
4/7/2025	AVXL Anavex Life Sciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00 ➝ $46.00

(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	$1.42 per share	N/A
NUVB Nuvation Bio	$10.96M	69.24	N/A	N/A	$2.76 per share	0.81
VIR Vir Biotechnology	$14.30M	43.98	N/A	N/A	$11.82 per share	0.38
YMAB Y-mAbs Therapeutics	$87.69M	1.99	N/A	N/A	$2.32 per share	1.66

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVXL Anavex Life Sciences	-$43M	-$0.55	N/A	N/A	N/A	N/A	-37.50%	-34.08%	N/A
NUVB Nuvation Bio	-$75.80M	-$2.35	N/A	N/A	N/A	N/A	-21.89%	-17.86%	N/A
VIR Vir Biotechnology	-$615.06M	-$4.22	N/A	N/A	N/A	-678.40%	-36.71%	-31.00%	7/30/2025 (Estimated)
YMAB Y-mAbs Therapeutics	-$21.43M	-$0.67	N/A	N/A	N/A	-28.22%	-24.61%	-18.49%	N/A

Latest YMAB, VIR, AVXL, and NUVB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q2 2025	AVXL Anavex Life Sciences	-$0.16	-$0.13	+$0.03	-$0.13	N/A	N/A
5/13/2025	Q1 2025	YMAB Y-mAbs Therapeutics	-$0.22	-$0.12	+$0.10	-$0.12	$19.97 million	$20.90 million
5/7/2025	Q1 2025	NUVB Nuvation Bio	-$0.16	-$0.16	N/A	-$0.16	$0.42 million	$3.08 million
5/7/2025	Q1 2025	VIR Vir Biotechnology	-$0.83	-$0.88	-$0.05	-$0.88	$8.59 million	$3.03 million
3/4/2025	Q4 2024	YMAB Y-mAbs Therapeutics	-$0.13	-$0.15	-$0.02	-$0.15	$26.70 million	$26.50 million
2/26/2025	Q4 2024	VIR Vir Biotechnology	-$0.85	-$0.76	+$0.09	-$0.76	$8.14 million	$12.37 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	N/A
NUVB Nuvation Bio	N/A	N/A	N/A	N/A	N/A
VIR Vir Biotechnology	N/A	N/A	N/A	N/A	N/A
YMAB Y-mAbs Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVXL Anavex Life Sciences	N/A	9.45	9.45
NUVB Nuvation Bio	N/A	9.57	9.57
VIR Vir Biotechnology	N/A	8.94	8.94
YMAB Y-mAbs Therapeutics	N/A	3.92	3.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVXL Anavex Life Sciences	31.55%
NUVB Nuvation Bio	61.67%
VIR Vir Biotechnology	65.32%
YMAB Y-mAbs Therapeutics	70.85%

Insider Ownership

Company	Insider Ownership
AVXL Anavex Life Sciences	11.40%
NUVB Nuvation Bio	29.93%
VIR Vir Biotechnology	15.60%
YMAB Y-mAbs Therapeutics	22.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVXL Anavex Life Sciences	40	85.37 million	75.71 million	Optionable
NUVB Nuvation Bio	60	338.68 million	319.50 million	Optionable
VIR Vir Biotechnology	580	138.24 million	116.24 million	Optionable
YMAB Y-mAbs Therapeutics	150	45.28 million	34.71 million	Optionable

YMAB, VIR, AVXL, and NUVB Headlines

Recent News About These Companies

Y-mAbs Therapeutics Inc (YMAB) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges

May 14 at 3:18 AM | finance.yahoo.com

Y-mAbs Therapeutics, Inc.: Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments

May 13 at 10:11 PM | finanznachrichten.de

Y-mAbs Therapeutics, Inc. (YMAB) Q1 2025 Earnings Call Transcript

May 13 at 1:35 PM | seekingalpha.com

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates

May 13 at 8:45 AM | zacks.com

Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025

May 13 at 7:05 AM | globenewswire.com

Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments

May 13 at 6:35 AM | globenewswire.com

Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)

May 7, 2025 | globenewswire.com

Why Y-mAbs Therapeutics, Inc.’s (YMAB) Stock Is Down 5.65%

May 6, 2025 | aaii.com

Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025

May 6, 2025 | globenewswire.com

Short Interest in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Drops By 16.1%

May 5, 2025 | marketbeat.com

2,861,825 Shares in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Acquired by Acorn Capital Advisors LLC

May 4, 2025 | marketbeat.com

Caligan Partners LP Has $13.84 Million Stock Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

May 3, 2025 | marketbeat.com

Renaissance Technologies LLC Raises Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

May 3, 2025 | marketbeat.com

Y-mAbs Therapeutics (YMAB) Projected to Post Earnings on Tuesday

May 1, 2025 | marketbeat.com

JPMorgan Chase & Co. Raises Stock Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

April 30, 2025 | marketbeat.com

Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to Decline

April 29, 2025 | zacks.com

Boothbay Fund Management LLC Buys 136,264 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

April 29, 2025 | marketbeat.com

Y-mAbs Therapeutics announces presentation of PK data of CD38-SADA

April 28, 2025 | markets.businessinsider.com

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) latest 13% decline adds to one-year losses, institutional investors may consider drastic measures

April 27, 2025 | finance.yahoo.com

Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting

April 27, 2025 | globenewswire.com

Brookline Capital Management Weighs in on YMAB Q1 Earnings

April 27, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
By Jeffrey Neal Johnson | April 25, 2025
View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
By Nathan Reiff | April 30, 2025
View Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
By Sam Quirke | May 13, 2025
View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
Gold Rally Continues: These 3 Mining Stocks Are Likely to Benefit
By Chris Markoch | April 16, 2025
View Gold Rally Continues: These 3 Mining Stocks Are Likely to Benefit
Medtronic: A Dividend Aristocrat With Stability and Innovation
By Jeffrey Neal Johnson | April 22, 2025
View Medtronic: A Dividend Aristocrat With Stability and Innovation

YMAB, VIR, AVXL, and NUVB Company Descriptions

Anavex Life Sciences NASDAQ:AVXL

$8.37 +0.20 (+2.45%)

As of 04:00 PM Eastern

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Nuvation Bio NYSE:NUVB

$2.24 +0.07 (+3.23%)

As of 03:59 PM Eastern

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

Vir Biotechnology NASDAQ:VIR

$4.55 +0.05 (+1.11%)

As of 04:00 PM Eastern

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Y-mAbs Therapeutics NASDAQ:YMAB

$3.86 +0.22 (+6.04%)

As of 04:00 PM Eastern

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time